RPG Life Sciences Limited (RPGLIFE.BO)
INR 2039.75
(1.94%)
INR 2039.75
(1.94%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -364.7 Million INR | -47.0% |
| 2022 | -248.1 Million INR | 55.7% |
| 2021 | -560 Million INR | -46.06% |
| 2020 | -383.4 Million INR | -442.93% |
| 2019 | 111.8 Million INR | -69.06% |
| 2018 | 361.3 Million INR | -33.23% |
| 2017 | 541.1 Million INR | 23.31% |
| 2016 | 438.8 Million INR | 96.24% |
| 2015 | 223.6 Million INR | -30.26% |
| 2014 | 320.6 Million INR | 140.33% |
| 2013 | 133.4 Million INR | -71.51% |
| 2012 | 468.3 Million INR | -12.76% |
| 2011 | 536.8 Million INR | 120.72% |
| 2010 | 243.2 Million INR | -49.6% |
| 2009 | 482.51 Million INR | -14.1% |
| 2008 | 561.72 Million INR | -22.24% |
| 2007 | 722.33 Million INR | -5.81% |
| 2006 | 766.89 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.25 Billion INR | 445.13% |
| 2023 Q4 | -364.7 Million INR | -135.77% |
| 2023 FY | -364.7 Million INR | -47.0% |
| 2023 Q2 | -223.2 Million INR | -119.44% |
| 2023 Q3 | 1.01 Billion INR | 556.77% |
| 2023 Q1 | 1.14 Billion INR | 562.72% |
| 2022 Q2 | -504.4 Million INR | -188.58% |
| 2022 Q4 | -248.1 Million INR | -130.68% |
| 2022 Q3 | 808.7 Million INR | 260.33% |
| 2022 Q1 | 569.4 Million INR | 201.68% |
| 2022 FY | -248.1 Million INR | 55.7% |
| 2021 Q1 | 407.5 Million INR | 206.29% |
| 2021 Q3 | 607.7 Million INR | 423.93% |
| 2021 FY | -560 Million INR | -46.06% |
| 2021 Q4 | -560 Million INR | -192.15% |
| 2021 Q2 | -187.6 Million INR | -146.04% |
| 2020 Q4 | -383.4 Million INR | -1103.66% |
| 2020 Q1 | 5.4 Million INR | -95.17% |
| 2020 Q2 | 4 Million INR | -25.93% |
| 2020 Q3 | 38.2 Million INR | 855.0% |
| 2020 FY | -383.4 Million INR | -442.93% |
| 2019 FY | 111.8 Million INR | -69.06% |
| 2019 Q4 | 111.8 Million INR | 1200.0% |
| 2019 Q2 | 108.1 Million INR | 2821.62% |
| 2019 Q3 | 8.6 Million INR | -92.04% |
| 2019 Q1 | 3.7 Million INR | -98.98% |
| 2018 Q2 | 461.5 Million INR | 41854.55% |
| 2018 Q1 | 1.1 Million INR | -99.8% |
| 2018 FY | 361.3 Million INR | -33.23% |
| 2018 Q4 | 361.3 Million INR | 3914.44% |
| 2018 Q3 | 9 Million INR | -98.05% |
| 2017 FY | 541.1 Million INR | 23.31% |
| 2017 Q4 | 541.1 Million INR | 2689.18% |
| 2017 Q1 | 16 Million INR | -96.35% |
| 2017 Q2 | 494.8 Million INR | 2992.5% |
| 2017 Q3 | 19.4 Million INR | -96.08% |
| 2016 Q2 | -1.3 Million INR | -116.25% |
| 2016 Q1 | 8 Million INR | -96.42% |
| 2016 Q4 | 438.8 Million INR | 135.53% |
| 2016 Q3 | 186.3 Million INR | 14430.77% |
| 2016 FY | 438.8 Million INR | 96.24% |
| 2015 Q4 | 223.6 Million INR | 2412.36% |
| 2015 Q2 | 287.7 Million INR | 3895.83% |
| 2015 Q1 | 7.2 Million INR | -97.75% |
| 2015 FY | 223.6 Million INR | -30.26% |
| 2015 Q3 | 8.9 Million INR | -96.91% |
| 2014 Q1 | 7 Million INR | -94.75% |
| 2014 FY | 320.6 Million INR | 140.33% |
| 2014 Q4 | 320.6 Million INR | 1968.39% |
| 2014 Q3 | 15.5 Million INR | -94.9% |
| 2014 Q2 | 304.2 Million INR | 4245.71% |
| 2013 Q3 | 5.9 Million INR | -95.56% |
| 2013 Q4 | 133.4 Million INR | 2161.02% |
| 2013 FY | 133.4 Million INR | -71.51% |
| 2013 Q1 | 7.8 Million INR | -98.33% |
| 2013 Q2 | 132.9 Million INR | 1603.85% |
| 2012 Q4 | 468.3 Million INR | 0.0% |
| 2012 FY | 468.3 Million INR | -12.76% |
| 2012 Q2 | 223.6 Million INR | 0.0% |
| 2011 FY | 536.8 Million INR | 120.72% |
| 2010 FY | 243.2 Million INR | -49.6% |
| 2009 FY | 482.51 Million INR | -14.1% |
| 2008 FY | 561.72 Million INR | -22.24% |
| 2007 FY | 722.33 Million INR | -5.81% |
| 2006 FY | 766.89 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 109.434% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 109.875% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 87.17% |
| Granules India Limited | 9.28 Billion INR | 103.927% |
| Indoco Remedies Limited | 6.47 Billion INR | 105.631% |
| Achyut Healthcare Limited | -3.74 Million INR | -9635.718% |
| Ajanta Pharma Limited | -954.9 Million INR | 61.808% |
| Alkem Laboratories Limited | -1.6 Billion INR | 77.339% |
| Alpa Laboratories Limited | 35.36 Million INR | 1131.304% |
| Brooks Laboratories Limited | 49.48 Million INR | 836.991% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 92.724% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 111.055% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 68.499% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 102.824% |
| Eris Lifesciences Limited | 13.8 Billion INR | 102.642% |
| FDC Limited | -57.75 Million INR | -531.493% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 91.489% |
| Gufic Biosciences Limited | 3.19 Billion INR | 111.417% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 91.219% |
| Ipca Laboratories Limited | 11.41 Billion INR | 103.195% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 73.761% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 118.868% |
| Lasa Supergenerics Limited | 205.79 Million INR | 277.212% |
| Laurus Labs Limited | 24.38 Billion INR | 101.496% |
| Lupin Limited | 17.19 Billion INR | 102.121% |
| Mankind Pharma Limited | -9.9 Billion INR | 96.319% |
| Medicamen Biotech Limited | 160.31 Million INR | 327.488% |
| Medico Remedies Limited | 78.67 Million INR | 563.541% |
| Megasoft Limited | 1.28 Billion INR | 128.369% |
| NATCO Pharma Limited | -5.81 Billion INR | 93.73% |
| Piramal Pharma Limited | 42.27 Billion INR | 100.863% |
| Sigachi Industries Limited | 859.94 Million INR | 142.409% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 99.497% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 351.559% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 889.206% |
| Unichem Laboratories Limited | 931.91 Million INR | 139.134% |
| Wanbury Limited | 1.1 Billion INR | 132.978% |
| Windlas Biotech Limited | -273.04 Million INR | -33.57% |
| ZIM Laboratories Limited | 983.6 Million INR | 137.078% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 109.323% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 61.276% |
| Divi's Laboratories Limited | -39.77 Billion INR | 99.083% |
| Hester Biosciences Limited | 2.29 Billion INR | 115.921% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 84.468% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -46.588% |
| Bal Pharma Limited | 1.26 Billion INR | 128.863% |
| Strides Pharma Science Limited | 23.25 Billion INR | 101.568% |
| Venus Remedies Limited | -267.7 Million INR | -36.235% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 113.963% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 105.923% |
| Shilpa Medicare Limited | 9.06 Billion INR | 104.021% |
| Aarti Drugs Limited | 5.54 Billion INR | 106.573% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 66.885% |
| Suven Life Sciences Limited | -1.63 Billion INR | 77.663% |
| Ind-Swift Limited | 9.5 Billion INR | 103.835% |
| Valiant Laboratories Limited | -295.03 Million INR | -23.614% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 112.927% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 103.636% |
| Themis Medicare Limited | 764.96 Million INR | 147.676% |
| Hikal Limited | 7.96 Billion INR | 104.578% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 101.146% |
| Sequent Scientific Limited | 4.17 Billion INR | 108.728% |
| Novartis India Limited | -5.89 Billion INR | 93.809% |
| Wockhardt Limited | 18.27 Billion INR | 101.996% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 101.347% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -1877.122% |
| Neuland Laboratories Limited | -214.05 Million INR | -70.374% |
| Morepen Laboratories Limited | -231.17 Million INR | -57.76% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 403.818% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 137.374% |